State of the science: an update on renal cell carcinoma - Test2 - elhamkhani - TriplyDB

State of the science: an update on renal cell carcinoma

State of the science: an update on renal cell carcinoma

http://www.wikidata.org/entity/Q24630685

about

The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy The PI3K/AKT Pathway and Renal Cell Carcinoma Activators of G protein signaling in the kidney Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities The bigger the better: determining nephron size in kidney Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics Cadmium alters the formation of benzo[a]pyrene DNA adducts in the RPTEC/TERT1 human renal proximal tubule epithelial cell line Expression of von Hippel-Lindau tumor suppressor protein (pVHL) characteristic of tongue cancer and proliferative lesions in tongue epithelium Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma.Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma.Functional significance of erythropoietin in renal cell carcinoma.DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma.Prognostic value of EZH2 expression and activity in renal cell carcinoma: a prospective study.Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma.Specific genomic aberrations predict survival, but low mutation rate in cancer hot spots, in clear cell renal cell carcinoma Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma Inactivation of the tumor suppressor gene von Hippel-Lindau (VHL) in granulocytes contributes to development of liver hemangiomas in a mouse model.Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT).High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma Oncogenic MicroRNAs Characterization in Clear Cell Renal Cell Carcinoma.Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: involvement of HIF-1α degradation.Essential role for SphK1/S1P signaling to regulate hypoxia-inducible factor 2α expression and activity in cancer.Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer Prognostic Value of Plasma and Urine Glycosaminoglycan Scores in Clear Cell Renal Cell Carcinoma.Racial difference in histologic subtype of renal cell carcinoma.Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling.Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrence.Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma.Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.RLIP76 Targeted Therapy for Kidney Cancer Immunologic and clinical effects of targeting PD-1 in lung cancer.An emerging understanding of long noncoding RNAs in kidney cancer.Resistance to anti-angiogenic agents: a brief review of mechanisms and consequences.Identification and validation of dysregulated metabolic pathways in metastatic renal cell carcinoma.Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.

P2860

Q26783291-F387B236-EEA6-4078-9A7E-65D1940872AE Q26800216-9461D709-876F-40DD-BABA-13E182572BEC Q26824228-672746F9-CA40-4C1C-B9D4-9536E3D246BA Q26852437-92BF3B51-70AB-4DBE-B885-AAB1486B6797 Q27026016-C54810AB-B28B-434C-A54D-BBADA246E12A Q28393614-DB406973-DEB6-49EC-8A57-9B5B0ED23764 Q28654305-5B2AD9EB-3E1D-4083-B9F4-7DCBD138AD7A Q33733536-E29AEC9A-3E25-4AFB-A3A5-7112F75E3558 Q34077263-5C2A16CD-EAD0-4C65-8397-C101CF50035F Q34405226-7F14B953-0D50-400C-9EBA-FF76322B62B1 Q34543726-4948E9D8-B43C-4F1C-A459-03807689629E Q34694198-0DAECD0D-1836-4D4F-B7E6-45F6F53B2C28 Q35060552-35030D0E-D5F8-4CA2-BA94-D7C5BE559610 Q35144490-AD3AB340-8AAA-4036-BDEF-D8B6E15F5D4F Q35236736-6529ED09-889F-4ADC-B001-BEDE2EBCCBA0 Q35606411-EFA1A496-336B-4D71-8531-8EE5CDE193E6 Q35948290-25E846A5-ABBA-47ED-97F2-250FED2D8042 Q36161809-B887D238-F1C1-43AB-BE93-97BAB50F28BA Q36191526-02F88A7F-DD7E-40D0-BE77-CD74911655E9 Q36222951-34C654D5-2870-4BA4-B93C-CA7E8500CDA5 Q36231927-CC17BE1B-49CD-448D-B3A9-84BD721C3EA9 Q36404165-6EFC6627-0519-409D-A7F0-0C8183C3DB0C Q36445513-33F701E1-D2DD-416F-9E8E-3CDD1FDF440F Q36545983-3A67FE4B-64DB-42C3-AE18-B276000400D2 Q36748690-051C5A9E-710D-4360-AA2B-5CD2A5906370 Q36818377-ED3F366C-1F3F-4BD2-B614-332CA064D417 Q37081930-0BFCA409-A9FF-4BD7-9CD1-363F05AB54D8 Q37433431-1CDB6550-048E-4323-96D0-776383E9E4B1 Q37482609-6339F08B-1965-4D5F-80C4-3932CA984AD8 Q37536932-CD3557C3-6D40-49E3-A0D6-D24483F07E84 Q37550216-20185117-DE1A-42E0-B099-1126D8EB4595 Q37616743-366CCAC1-90EB-405E-AB4E-7A691EED3D91 Q37627446-52FCBE1A-B706-4EE7-8ED9-17E81DCCFF5E Q37709012-D7E26737-C9F2-4D4E-8434-CCA9DEB18357 Q37741408-31F20B53-3346-40D4-8FFA-74CEA9710F4A Q38201196-FD3B1944-D486-44A0-91F6-139AD05CF55A Q38210909-CF63233D-56C1-48CC-8A50-CDBE09792C97 Q38390060-E4D5444D-AC38-4E91-8F19-24DA52D8EFCD Q38484441-71C49332-599C-448B-AB3C-8121932CBD8B Q38704070-649F219A-78E3-4C66-9EA3-140EA9BEACF9

P2860

State of the science: an update on renal cell carcinoma

http://www.wikidata.org/entity/Q24630685

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

State of the science: an update on renal cell carcinoma

@ast

State of the science: an update on renal cell carcinoma

@en

State of the science: an update on renal cell carcinoma

@nl

type

label

State of the science: an update on renal cell carcinoma

@ast

State of the science: an update on renal cell carcinoma

@en

State of the science: an update on renal cell carcinoma

@nl

prefLabel

State of the science: an update on renal cell carcinoma

@ast

State of the science: an update on renal cell carcinoma

@en

State of the science: an update on renal cell carcinoma

@nl

P1433

Q24630685-07044746-4669-44F6-A6FF-1E48EB783C53

P1476

Q24630685-6B8289CE-805D-4081-B692-9864AB4E7470

P2093

Q24630685-00305AC3-1888-4218-A65E-1AFF3CA67622

Q24630685-0EDB9A39-4BBE-4F74-ACA9-C8D84E28F533

Q24630685-27891A97-42D0-4ECC-9444-EFDD97286A1E

Q24630685-3A335651-292A-488C-A3B2-7D3E5B1F77E8

Q24630685-3E2BA725-3B2E-4F57-9F29-5D67C5E4A120

Q24630685-42EA5A6C-FA4E-4136-A93B-0F4BE79F72D9

Q24630685-453D5D70-3AB1-4724-9DB6-7F39384631A3

Q24630685-498869F5-A2C5-45EB-8180-582F4B34CE5F

Q24630685-7E19CAF3-5763-474B-9EF9-A6D2A26220EA

Q24630685-94C64A28-1297-495A-B87F-ECD4A49BC849

P2860

Q24630685-02876273-A22D-4899-A8A5-D61DE7633318

Q24630685-03A61025-2739-463E-8A4F-4E840BCA819D

Q24630685-03B69B2E-F28C-4A61-B7B1-D0FCA4B59775

Q24630685-03DB249C-1A9F-4D23-A750-461475DE882C

Q24630685-04BF4AC8-912E-4815-8974-0B4450CCCA06

Q24630685-067B4634-084D-41EA-8AEB-41AAF5B5FF2B

Q24630685-08112E9F-DE49-4AFE-8750-E262BC77D00D

Q24630685-0AB9878D-8E9B-4B01-A969-1C0853F32174

Q24630685-0B0725FF-B00C-41E1-A88A-CD4C1BD8E540

Q24630685-0B11D62A-4196-4168-8A6F-5442E492861A

P304

Q24630685-19CE4C41-0694-49C5-B633-46C7746876C3

P31

Q24630685-668114AB-7B94-49DA-8D38-C8A2EB78AC06

P3181

Q24630685-0F388C53-62C4-4FAF-A95F-DF5CDCF5BD64

P356

Q24630685-348B3305-83A9-4E80-9C5E-17DCF6B73DDC

P407

Q24630685-784F355B-B6F6-4628-A8A0-A500EAF24BF4

P433

Q24630685-F707E11E-E4B4-4EFE-AF96-1C095C5EDEA3

P478

Q24630685-2F67FBD9-8F73-426A-99A1-2B2749AAB514

P50

Q24630685-1C42E47D-D78A-4893-850D-E13732E34029

Q24630685-867501AF-550D-4FD3-AEF5-DC7A5999DA15

P577

Q24630685-156814A5-08DB-4FCF-A4E9-7E92CA1222AD

P698

Q24630685-711531CA-C955-46B5-81EB-800643DCFAAD

P932

Q24630685-1BD769D0-7A24-4895-A5AC-F4BF942D45F3

P3181

P356

1541-7786.MCR-12-0117

P1433

Molecular Cancer Research

P1476

State of the science: an update on renal cell carcinoma

@en

P2093

Amado J Zurita

http://www.w3.org/2001/XMLSchema#string

Amato J Giaccia

http://www.w3.org/2001/XMLSchema#string

Armin Pause

http://www.w3.org/2001/XMLSchema#string

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Cheryl L Walker

http://www.w3.org/2001/XMLSchema#string

Eric Jonasch

http://www.w3.org/2001/XMLSchema#string

Ghada Kurban

http://www.w3.org/2001/XMLSchema#string

Ian J Davis

http://www.w3.org/2001/XMLSchema#string

James Brugarolas

http://www.w3.org/2001/XMLSchema#string

Michael B Atkins

http://www.w3.org/2001/XMLSchema#string

P2860

VHL type 2B mutations retain VBC complex form and function

Immunotherapy for advanced renal cell cancer

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

Selectivity of chromatin-remodelling cofactors for ligand-activated transcription

HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity

Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids

SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth

The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1

NEDD8 acts as a 'molecular switch' defining the functional selectivity of VHL

Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth.

P304

859-80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

892013

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1541-7786.MCR-12-0117

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P Andrew Futreal

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22638109

http://www.w3.org/2001/XMLSchema#string

P932

3399969

http://www.w3.org/2001/XMLSchema#string